Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

49.77USD
12:48pm EDT
Change (% chg)

$0.36 (+0.73%)
Prev Close
$49.41
Open
$49.02
Day's High
$50.12
Day's Low
$48.94
Volume
532,395
Avg. Vol
1,338,599
52-wk High
$50.37
52-wk Low
$39.28

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $73,559.50
Shares Outstanding(Mil.): 1,488.76
Dividend: 0.24
Yield (%): 1.94

Financials

  ABT.N Industry Sector
P/E (TTM): 37.02 35.83 39.81
EPS (TTM): 1.33 -- --
ROI: 6.22 17.03 16.23
ROE: 8.95 17.93 17.36
Search Stocks

Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source

TEL AVIV, June 23 - Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said.

23 Jun 2015

Teva raises stake in Mylan as three-way takeover battle heats up

- Israel's Teva Pharmaceutical Industries Ltd has raised its stake in Mylan N.V. to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.

19 Jun 2015

Abbott to vote for Mylan's acquisition of Perrigo

- Mylan NV's largest stakeholder, Abbott Laboratories , said it would back Mylan's proposed acquisition of Perrigo Co Plc , potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .

16 Jun 2015

REFILE-UPDATE 1-Abbott to vote for Mylan's acquisition of Perrigo

June 16 - Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .

16 Jun 2015

PRESS DIGEST- New York Times business news - May 26

May 26 - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

26 May 2015

Fitch Downgrades Abbotts's L-T IDR to 'A'; Outlook Revised to Stable

(The following statement was released by the rating agency) CHICAGO, May 18 (Fitch) Fitch Ratings has downgraded Abbott Laboratories' (Abbott) long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating Outlook to Stable from Negative. In addition, the company's short-term IDR has been affirmed at 'F1'. Abbott had $8.9 billion in outstanding debt at March 31, 2015. A full list of Fitch's ratings actions follows at the end of this release. KEY RATING DRIVERS -- Fitch exp

18 May 2015

AstraZeneca digs into precision medicine with lung, heart deals

LONDON, May 13 - AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease.

12 May 2015

Mylan reports profit, maintains commitment to acquire Perrigo

May 5 - Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland-based Perrigo Co.

05 May 2015

Abbott says its payoff from Mylan deal surged

- Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

UPDATE 1-Abbott says its payoff from Mylan deal surged

April 22 - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $98.11 -0.33
Pfizer Inc. (PFE.N) $33.33 -0.04
Novartis AG (NOVN.VX) CHF92.95 -0.10
Merck & Co., Inc. (MRK.N) $57.36 -0.31
Sanofi SA (SASY.PA) €87.16 -1.02
AstraZeneca plc (AZN.L) 4,149.00p -18.00
GlaxoSmithKline plc (GSK.L) 1,342.00p -5.50
Eli Lilly and Co (LLY.N) $86.11 -0.03
Amgen, Inc. (AMGN.OQ) $155.04 +1.78
Boston Scientific Corporation (BSX.N) $17.58 +0.01

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$49.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks